Martell is an early-stage cancer diagnostic company developing biomarker immunoassay tests to guide cancer care. Using our flagship product, HERTEST, clinicians receive real-time feedback on the progress of over 350K cancer patients annually, and could monitor over 3M patients per year for cancer recurrence. Currently, HERTEST is offered for $250 through our CLIA- certified reference lab in Roseville, MN and we are ready for product launch.